TrialBMJ open2022

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.

Tadashi Matsushita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.